| Autor: |
Sahith Reddy, Thotamgari, Udhayvir Singh, Grewal, Aakash R, Sheth, Akhilesh, Babbili, Paari, Dominic |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Cardiovascular Endocrinology & Metabolism. 11 |
| ISSN: |
2574-0954 |
| DOI: |
10.1097/xce.0000000000000265 |
| Popis: |
The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) in mitigating the risk of atrial fibrillation (AF) remains unknown. We interrogated the Food and Drug Administration's Adverse Event Reporting System (FAERS) database to study the association between AF-related adverse events and the use of GLP-1 RA and DPP-4i. A signal of disproportionate reporting of AF was detected with the DPP-4i group compared with all the other drugs in the FAERS database [ROR, 2.56; 95% confidence interval (CI), 2.10-3.12], whereas there was no disproportionality signal detected with the GLP-1 RA group (ROR, 0.90; 95% CI, 0.78-1.03) although liraglutide showed a significant disproportionality signal (ROR, 2.51; 95% CI, 2.00-3.15). Our analysis supports the existing body of literature demonstrating the cardiac safety of GLP-1 RA but raises concerns about the apparent increase in the risk of AF associated with DPP-4i. Further clinical and translational studies are needed to validate these findings. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
